Tejin Limited and Axcelead, Inc. jointly announced today that they have decided to name their drug discovery research joint venture "Axcelead Tokyo West Partners, Inc.”, which is scheduled to be established and commence its operations on April 1, 2024.
Axcelead TWP aims to grow as a comprehensive drug discovery support service provider by tapping into demand from drug discovery players in Japan and overseas, leveraging the strengths of its solid foundation based on the drug discovery expertise, knowledge, technologies and assets held by Teijin and Axcelead.
In promoting its business, Axcelead TWP will work closely with Axcelead Drug Discovery Partners, an integrated drug discovery contract research organisation affiliated with Axcelead, to meet the needs of diverse drug discovery players and provide high-quality solutions.
This basic agreement, which accords with Axcelead's concept of co-creating drug discovery platforms, responds to the global trend of horizontal specialisation in non-clinical research and new forms of outsourced research.
Teijin and Axcelead will proceed with preparations for the establishment of Axcelead TWP and the start of its operations.
